The goal of Tumor Immunology Training Program (TITP) is to prepare predoctoral students for a career in the application of immunological approaches to the understanding, prevention, diagnosis, and treatment of cancer. With the recent breakthroughs in understanding the significant role of endogenous anti-tumor immunity in cancer patients, preventive anti-cancer vaccines (e.g. the anti-HPV vaccine Gardasil(r)), and clinically effective immunotherapy (e.g. the prostate cancer vaccine Provenge(r), the immunomodulator ipilimumab in melanoma, and genetically engineered T cells in chronic lymphocytic leukemia), future scientific leaders in tumor immunology must not only be well-trained immunologists - they must also have a solid foundation in understanding how basic immunological concepts apply to the clinical arena of human beings with cancers. Toward this end, the unique, cancer-focused program of the TITP provides trainees with an advanced broad-based tumor immunology education that stresses the importance of training that spans the continuum from basic?translational?clinical research. The uniqueness of this training program is further augmented by the integration of an academic program comprised of diverse faculty within the setting of a world-renowned, NCI- designated, Comprehensive Cancer Center. Trainees are exposed to a broad perspective of cancer-related issues including cancer incidence and survival, the spectrum of scientific approaches to cancer, and the realities of patient care. Furthermore, the training experience TITP students receive is augmented by the close proximity of Roswell Park Cancer Institute to the University at Buffalo. The primary mission of the proposed training grant is to support students during their third and fourth year of graduate study. The funds requested in this renewal application cover stipends and tuition costs for 4 predoctoral students per year. This funding is crucial to continuing the upward trajectory experienced over 11 years of NRSA training grant support in the quality and diversity of predoctoral trainees focused on complex immunological questions in cancer. NRSA- supported trainees are prepared for a competitive research career through didactic courses in cancer biology and tumor immunology as well as in grantsmanship, scientific writing, and ethical conduct of research Degree conferral is dependent on preparation of a research proposal, as part of the preliminary examination requirement, and publication of a first-authored report of original findings. Students who successfully complete this training program will be well versed in all aspects of tumor immunology and will have the solid foundation upon which to build cancer-focused research efforts, guided by a clear vision of the impact on human cancers.

Public Health Relevance

Predoctoral training provided by the Tumor Immunology Training Program (TITP) is directly relevant to public health. Cancer remains a serious public health problem in the U.S. and worldwide, and it is increasingly evident that immune approaches will have a major impact in cancer prevention, diagnosis and treatment. The TITP's mission addresses a critical need to train the next generation of scientists with expertise in the fundamental principles of tumor immunology in order to advance understanding of the longstanding human cancer problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
2T32CA085183-11
Application #
8414592
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2000-04-01
Project End
2018-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$151,963
Indirect Cost
$8,650
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Szender, J Brian; Emmons, Tiffany; Belliotti, Sarah et al. (2017) Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecol Oncol 146:491-497
Twum, Danielle Y F; Burkard-Mandel, Lauren; Abrams, Scott I (2017) The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease. J Leukoc Biol 102:307-315
Netherby, Colleen S; Abrams, Scott I (2017) Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease. Cancer Immunol Immunother 66:989-996
Leigh, Nicholas D; O'Neill, Rachel E; Du, Wei et al. (2017) Host-Derived CD70 Suppresses Murine Graft-versus-Host Disease by Limiting Donor T Cell Expansion and Effector Function. J Immunol 199:336-347
Bucsek, Mark J; Qiao, Guanxi; MacDonald, Cameron R et al. (2017) ?-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res 77:5639-5651
Netherby, Colleen S; Messmer, Michelle N; Burkard-Mandel, Lauren et al. (2017) The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production. J Immunol 198:4129-4139
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2017) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol :
Singel, Kelly L; Segal, Brahm H (2016) Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol Rev 273:329-43
Singel, Kelly L; Segal, Brahm H (2016) NOX2-dependent regulation of inflammation. Clin Sci (Lond) 130:479-90
Fink, E E; Mannava, S; Bagati, A et al. (2016) Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells. Leukemia 30:104-11

Showing the most recent 10 out of 51 publications